肾病综合征患儿他克莫司血药浓度影响因素分析Analyzing Influence Factors of Tacrolimus Concentration in Population of Pediatric Nephrotic Syndrome
何艳玲,莫小兰,吴端仪,李嘉丽,李颖杰,侯连兵
HE Yanling,MO Xiaolan,WU Duanyi,LI Jiali,LI Yingjie,HOU Lianbing
摘要(Abstract)：
目的探讨儿童肾病综合征患者服用他克莫司的血药浓度的影响因素。方法采用酶增强免疫分析法测定他克莫司的全血浓度。收集某院2011-01~2012-12期间服用他克莫司的肾病综合征患儿的血药浓度、剂量以及年龄、性别、红细胞压积、血红蛋白浓度等数据。用SPSS软件分析年龄、性别、红细胞压积、血红蛋白和浓度、剂量间的相关性。结果年龄、性别和给药剂量间存在相关性(P<0.05)。幼儿期所需他克莫司剂量显著高于学龄前期、学龄期和青少年期。青少年期所需给药剂量最小。女性所需给药剂量大于男性患儿。红细胞压积、血红蛋白不影响血药浓度。结论年龄、性别影响肾病综合征患儿的他克莫司剂量,临床需综合评估患儿,以给予合适的初始剂量,及时进行血药浓度监测,适时调整剂量。
OBJECTIVE To analyze the influence factors of concentration of tacrolimus in population of pediatric nephrotic syndrome. METHODS Concentrations of tacrolimus in whole blood were determined by enzyme-multiplied immunoassay technique method. Data of concentrations,dose,age,sex,hematocrit and hemoglobin were collected from 2011 to 2012 in population of pediatric nephrotic syndrome in a hospital. The correlations between concentration,dose and age,sex,hematocrit,hemoglobin were analyzed by SPSS software. RESULTS Correlations were found between dose and age,sex( P < 0. 05). Infant needed higher dose of tacrolimus than children of pre-school age,children of school age,and adolescent. Adolescent needed the lowest dose of tacrolimus. Girls needed higher dose than boys. Concentration was not affected by hematocrit and hemoglobin. CONCLUSION Age and sex might affect the whole blood concentration of tacrolimus of pediatric nephrotic syndrome. Physicians and clinical pharmacists should evaluated children of nephrotic syndrome generally to give the proper initial dose and adjust dose timely after therapeutic drug monitoring.
关键词(KeyWords)：
肾病综合征;儿童;他克莫司;血药浓度
nephrotic syndrome;pediatric;tacrolimus;concentration
基金项目(Foundation): 广东省医院药学研究基金——朗声免疫专项(2012LS11)
作者(Author):
何艳玲,莫小兰,吴端仪,李嘉丽,李颖杰,侯连兵
HE Yanling,MO Xiaolan,WU Duanyi,LI Jiali,LI Yingjie,HOU Lianbing
参考文献(References)：
- [1]Filler G,Young E,Geier P,et al.Is there really an increase in nonminimal change nephrotic syndrome in children[J].Am J Kidney Dis,2003,42:1107-1113.
- [2]石永兵,冯胜.原发性肾病综合征免疫抑制药的研究[J].临床药物治疗杂志,2011,04:15-18.
- [3]郑志方,任榕娜,余自华.他克莫司在治疗儿童原发性肾病综合征中的应用[J].中国实用儿科杂志,2011,02:151-153.
- [4]中华医学会儿科学分会肾脏病学组.儿童常见肾脏疾病诊治循证指南(一):激素敏感,复发,依赖肾病综合征诊治循证指南(试行)[J].中华儿科杂志,2009,47:167-170.
- [5]Hesselink DA,van Schaik RH,van der Heiden IP,et al.Genetic polymorphisms of the CYP3A4,CYP3A5,and MDR-1genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus[J].Clin Pharmacol Ther,2003,74(3):245-254.
- [6]Renders L,Frisman M,Ufer M,et al.CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients[J].Clin Pharmacol Ther,2007,81(2):228-234.
- [7]Fredericks S,Moreton M,Reboux S,et al.Multidrug resistance gene-1(MDR-1)haplotypes have a minor influence on tacrolimus dose requirements[J].Transplantation,2006,82(5):705-708.
- [8]黄松明.泌尿系统疾病[M].王卫平.儿科学.北京:人民卫生出版社,2013:327-328.
- [9]Taylor PJ,Jones A,Balderson GA,et al.Sensitive,specific quantitative analysis of tacrolimus(FK506)in blood by liquid chromatography-electrospray tandem mass spectrometry[J].Clin Chem,1996,42(2):279-285.
- [10]Venkataramanan R,Swaminathan A,Prasad T,et al.Clinical pharmacokinetics of tacrolimus.Clin Pharmacokinet,1995,29(6):404-430.
- [11]任斌,黎曙霞,洪晓丹,等.80例肾移植患者他克莫司血药浓度数据分析[J].中国药房,2004(11):42-43.
- [12]周永恒,石磊,唐镜波.影响他克莫司血药浓度的因素[J].中国药房,2005(24):1909-1911.
- [13]郝胜华.移植病人淋巴细胞P-gp表达水平的改变及其临床意义的研究[D].中南大学,2008.
- [14]Staatz CE,Tett SE.Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation[J].Clin Pharmacokinet,2004,43(10):623-653.
- [15]Wrighton SA,Brian WR,Sari MA,et al.Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5(HLp3)[J].Mol Pharmacol,1990,38(2):207-213.
- [16]陈艳梅,刘丽宏,马萍,等.他克莫司药代动力学参数的影响因素研究[J].山西医药杂志,2009,05:478-479.
- [17]张关敏,李良,陈文倩,等.他克莫司在中国肾移植患者中的群体药物动力学研究[J].药学学报,2008,07:695-701.
- [18]张弋,白帼珍,薛芳菁,等.他克莫司在儿童肝移植患者中的血药浓度及影响因素[J].中国医院药学杂志,2008,(19):1650-1653.
- [19]李嘉丽.相关基因多态性与肾移植患者他克莫司个体化用药的研究[D].中山大学,2010.